2017 issue 3-4

Back

Volume 33, issue 3-4

Review article

Vortioxetine or duloxetine – patient’s profile and individualization of therapy based on case reports

Piotr Baranowski1, Dorota Kuczborska-Majda1
1. „Dolnośląskie Centrum Zdrowia Psychicznego” sp. z o.o.
Farmakoterapia w Psychiatrii i Neurologii 2017, 33 (3–4), 239–250
Date of publication: 30-01-2018
DOI: http://dx.medra.org/10.17393/fpn.2017.12.002
Keywords: vortioxetine, duloxetine, depression, antidepressants

Abstract

Vortioxetine is a modern antidepressant with a broad receptor profile. In the US (Food and Drug Administration, FDA) and in Europe (European Medicines Agency, EMA) vortioxetine has been registered for the treatment of major depressive episodes in adults. Currently, however, trials are underway to extend the therapeutic indications for this drug. Duloxetine is a drug from the group of serotonin and noradrenaline reuptake inhibitors. Its registered indications include: major depressive disorders, diabetic neuropathic pain and generalized anxiety disorder. Both duloxetine and vortioxetine are registered for the treatment of adults.

Address for correspondence:
Dorota Kuczborska-Majda
„Dolnośląskie Centrum Zdrowia Psychicznego”
sp. z o.o.
Wybrzeże J. Conrada-Korzeniowskiego 18,
50-226 Wrocław, Poland
phone: +48 506066823
email: Dorota.Majda@interia.eu